Karyopharm Therapeutics Upgraded to Outperform by Oppenheimer

Karyopharm Therapeutics was upgraded on November 10, 2014 from “Perform” to “Outperform” by Oppenheimer.  Oppenheimer currently has a $53.00 target price on the stock which points to a potential upside of 25.77% from the stock’s previous close.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

Other Firms Covering Karyopharm Therapeutics

  • Barrington Research – BUY –  $54 price target
  • Wedbush – outperform – $50 price target
  • MLV & Co. – BUY – $54 price target